GYRE THERAPEUTICS, INC. cotiza a 6.77 USD y tiene una capitalización bursátil de $718M. En los últimos 12 meses ha facturado $119M con un margen de flujo de caja libre del -0.1%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and unde…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.12 | $-0.10 | $0.05 |
| Estimado | $-0.03 | $-0.06 | $-0.07 | $0.01 |
| Sorpresa | — | -100.0% | -42.9% | +400.0% |
| Métrica | GYRE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 95.3% | 57.0% | +38.3% |
| Operating Margin | 9.8% | -38.6% | +48.5% |
| Net Margin | 8.5% | -33.6% | +42.0% |
| FCF Margin | -0.1% | -13.9% | +13.7% |
| ROE | 9.3% | -40.4% | +49.7% |
| ROA | 6.0% | -32.0% | +38.0% |
| Current Ratio | 5.60 | 2.84 | +2.76 |
| Debt / Equity | — | 0.28 | — |